Skip to main content

BioMérieux, McKesson Reach Deal Targeting Antibiotic Stewardship, Sepsis Prevention

NEW YORK (360Dx) – McKesson Medical Surgical today announced a distribution agreement expanding access to certain BioMérieux products to US community hospitals.

The deal, said McKesson Medical Surgical, an affiliate of McKesson, highlights both firm's focus on antibiotic stewardship and sepsis prevention in hospital care settings. Three BioMérieux products and reagents will now be available through McKesson: the Vidas BRAHMS PCT, run on the Vidas 3 immunoanalyzer to guide antibiotic therapy in sepsis and lower respiratory tract infections; Bact/Alert and Fan Plus Media, which optimizes time to detection and microorganism recovery; and the Vitek 2 instrument for microbial identification and antibiotic susceptibility testing results with same-day turnaround time.

"This alliance enhances community hospital access to BioMérieux's best-in-class diagnostic solutions," BioMérieux Executive Vice President and General Manager Brian Armstrong said in a statement. "Tests like Vidas BRAHMS PCT can empower hospitals to improve antimicrobial stewardship and positively impact patient care, no matter what their size."

Financial and other terms of the deal were not disclosed.